Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eyetech Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Eyetech Pharmaceuticals believes that blocking angiogenesis is the best route to improved therapy for age-related macular degeneration and diabetic macular edema, degenerative conditions that frequently and quickly lead to serious vision loss and blindness. The company in-licensed a compound from Gilead Sciences, about to enter pivotal clinical trials, that it thinks does just that.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090389

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel